2. Academic Validation
  3. Active fragment assembly strategy enabling fast discovery of KRAS inhibitors against pancreatic cancer cells

Active fragment assembly strategy enabling fast discovery of KRAS inhibitors against pancreatic cancer cells

  • Eur J Med Chem. 2026 Jun 5:310:118807. doi: 10.1016/j.ejmech.2026.118807.
Pengli Zhang 1,  Lili Kong 1,  Xianghui Meng 2,  Yating Chen 1,  Yukun Jiao 1,  Zixuan Su 1,  Xiaorong Song 1,  Kan Ding 3,  Guoqin Xia 4
Affiliations

Affiliations

  • 1 Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, 528400, China.
  • 2 School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210000, China.
  • 3 Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, 528400, China. Electronic address: dingkan@simm.ac.cn.
  • 4 Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, 528400, China; School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 210000, China. Electronic address: xiaguoqin@simm.ac.cn.
PMID: 41931988 DOI: 10.1016/j.ejmech.2026.118807
Abstract

The escalating demand for efficient therapeutic development necessitates innovative strategies to accelerate drug discovery. This study employs an active fragment assembly (AFA) strategy to create a series of linear indoxadiazole compounds that serve as viable inhibitors for KRAS protein. Preliminary assessments indicate that compound 10b exhibits significant inhibitory activity in pancreatic Cancer cells harboring KRASG12C and KRASG12D mutations (ASPC-1, PANC-1 and Miapac-2) and excellent selectivity between cancerous and non-cancerous cells. Mechanistic studies reveal that 10b effectively downregulates the levels of phosphorylated Raf1, Akt, and ERK in the ASPC-1 and Miapac-2 Cancer cell lines. Additionally, molecular docking studies demonstrate a robust binding affinity of compound 10b with both KRASG12C and KRASG12D proteins. These findings provided unique pathways for investigating multi-target inhibitors aimed at mutated KRAS proteins, thereby advancing the development of innovative molecular therapies for cancers associated with KRAS mutations.

Keywords

AFA strategy; Indoxadiazole; KRAS.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z